Profound structural conservation of chemically cross-linked HIV-1 envelope glycoprotein experimental vaccine antigens.


Journal

NPJ vaccines
ISSN: 2059-0105
Titre abrégé: NPJ Vaccines
Pays: England
ID NLM: 101699863

Informations de publication

Date de publication:
13 Jul 2023
Historique:
received: 09 12 2022
accepted: 27 06 2023
medline: 14 7 2023
pubmed: 14 7 2023
entrez: 14 7 2023
Statut: epublish

Résumé

Chemical cross-linking is used to stabilize protein structures with additional benefits of pathogen and toxin inactivation for vaccine use, but its use has been restricted by the potential for local or global structural distortion. This is of particular importance when the protein in question requires a high degree of structural conservation for inducing a biological outcome such as the elicitation of antibodies to conformationally sensitive epitopes. The HIV-1 envelope glycoprotein (Env) trimer is metastable and shifts between different conformational states, complicating its use as a vaccine antigen. Here we have used the hetero-bifunctional zero-length reagent 1-Ethyl-3-(3-Dimethylaminopropyl)-Carbodiimide (EDC) to cross-link two soluble Env trimers, selected well-folded trimer species using antibody affinity, and transferred this process to good manufacturing practice (GMP) for experimental medicine use. Cross-linking enhanced trimer stability to biophysical and enzyme attack. Cryo-EM analysis revealed that cross-linking retained the overall structure with root-mean-square deviations (RMSDs) between unmodified and cross-linked Env trimers of 0.4-0.5 Å. Despite this negligible distortion of global trimer structure, we identified individual inter-subunit, intra-subunit, and intra-protomer cross-links. Antigenicity and immunogenicity of the trimers were selectively modified by cross-linking, with cross-linked ConS retaining bnAb binding more consistently than ConM. Thus, the EDC cross-linking process improves trimer stability whilst maintaining protein folding, and is readily transferred to GMP, consistent with the more general use of this approach in protein-based vaccine design.

Identifiants

pubmed: 37443366
doi: 10.1038/s41541-023-00696-w
pii: 10.1038/s41541-023-00696-w
pmc: PMC10345191
doi:

Types de publication

Journal Article

Langues

eng

Pagination

101

Subventions

Organisme : NIAID NIH HHS
ID : UM1 AI144462
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI100663
Pays : United States

Informations de copyright

© 2023. The Author(s).

Références

J Exp Med. 2017 Sep 4;214(9):2573-2590
pubmed: 28847869
Nature. 2002 Dec 12;420(6916):678-82
pubmed: 12478295
J Biol Chem. 1975 Sep 25;250(18):7435-42
pubmed: 809435
Cell Rep. 2018 Sep 18;24(12):3324-3338.e5
pubmed: 30232012
Infect Immun. 1994 May;62(5):1830-4
pubmed: 7513307
Acta Crystallogr D Biol Crystallogr. 2010 Apr;66(Pt 4):486-501
pubmed: 20383002
PLoS Pathog. 2013 Sep;9(9):e1003618
pubmed: 24068931
Science. 2014 Nov 7;346(6210):759-63
pubmed: 25298114
Protein Sci. 2018 Jan;27(1):293-315
pubmed: 29067766
PLoS Pathog. 2018 May 10;14(5):e1006986
pubmed: 29746590
Nat Methods. 2012 Sep;9(9):853-4
pubmed: 22842542
Rev Med Virol. 2019 Nov;29(6):e2074
pubmed: 31334909
Sci Transl Med. 2020 Mar 18;12(535):
pubmed: 32188721
Nucleic Acids Res. 2015 Sep 18;43(16):e102
pubmed: 25977298
J Comput Chem. 2004 Oct;25(13):1605-12
pubmed: 15264254
Nature. 2014 Nov 6;515(7525):138-42
pubmed: 25186731
J Struct Biol. 2015 Nov;192(2):216-21
pubmed: 26278980
Nat Methods. 2017 Mar;14(3):290-296
pubmed: 28165473
Nat Rev Immunol. 2006 Jul;6(7):541-50
pubmed: 16799473
Front Immunol. 2020 Sep 23;11:579761
pubmed: 33072125
Nat Rev Immunol. 2019 Feb;19(2):77-78
pubmed: 30560910
Curr Opin HIV AIDS. 2017 May;12(3):241-249
pubmed: 28422788
Bioconjug Chem. 2009 Aug 19;20(8):1459-73
pubmed: 19606852
Cell Host Microbe. 2019 Jun 12;25(6):873-883.e5
pubmed: 31194940
J Virol. 2002 Sep;76(17):8875-89
pubmed: 12163607
Nat Methods. 2015 Oct;12(10):943-6
pubmed: 26280328
J Virol. 2015 Oct 28;90(2):813-28
pubmed: 26512083
Cell Rep. 2017 Aug 22;20(8):1805-1817
pubmed: 28834745
Science. 2009 Oct 9;326(5950):285-9
pubmed: 19729618
J Virol. 2013 Sep;87(18):10163-72
pubmed: 23843636
AIDS Res Hum Retroviruses. 1990 May;6(5):567-79
pubmed: 1694449
Trends Microbiol. 2020 Aug;28(8):655-667
pubmed: 32418859
J Virol. 1993 Jul;67(7):3978-88
pubmed: 7685405
Science. 2016 May 13;352(6287):828-33
pubmed: 27174988
Vaccine. 2013 Jun 24;31(29):2988-93
pubmed: 23664992
Blood. 2008 Aug 15;112(4):1461-71
pubmed: 18490516
PLoS Pathog. 2016 Aug 03;12(8):e1005767
pubmed: 27487086
Vaccine. 2011 Feb 17;29(9):1812-23
pubmed: 21215831
Acta Crystallogr D Biol Crystallogr. 2012 Apr;68(Pt 4):352-67
pubmed: 22505256
Curr Top Microbiol Immunol. 2015;386:151-80
pubmed: 25038938
Nat Rev Immunol. 2014 Jul;14(7):495-504
pubmed: 24948364
Vaccines (Basel). 2015 Apr 24;3(2):373-89
pubmed: 26343192
Elife. 2018 Nov 09;7:
pubmed: 30412051
AIDS Res Hum Retroviruses. 1994 Apr;10(4):359-69
pubmed: 7520721
Nat Commun. 2019 May 29;10(1):2355
pubmed: 31142746
Nat Med. 2006 Aug;12(8):905-7
pubmed: 16862151
AIDS Res Hum Retroviruses. 1995 May;11(5):533-9
pubmed: 7576908
Immunity. 2018 May 15;48(5):855-871
pubmed: 29768174
Vaccine. 2016 Apr 19;34(18):2129-34
pubmed: 26973066
Vaccine. 1994 May;12(7):579-81
pubmed: 8085372
Vaccine. 1996 Apr;14(5):359-68
pubmed: 8735545
J Struct Biol. 2005 Jul;151(1):41-60
pubmed: 15890530
Nat Microbiol. 2016 Nov 14;2:16199
pubmed: 27841852
Vaccine. 2007 Mar 8;25(12):2213-27
pubmed: 17240009
Nat Methods. 2017 Apr;14(4):331-332
pubmed: 28250466
Immunity. 2017 Apr 18;46(4):690-702
pubmed: 28423342
PLoS One. 2012;7(5):e36438
pubmed: 22590544
Cell. 2015 Dec 17;163(7):1702-15
pubmed: 26687358
Sci Adv. 2021 Jul 28;7(31):
pubmed: 34321200
Protein Sci. 2014 Jan;23(1):47-55
pubmed: 24265211
Structure. 2013 Oct 8;21(10):1735-42
pubmed: 24035711
Nature. 2011 Sep 22;477(7365):466-70
pubmed: 21849977
Immunol Rev. 2017 Jan;275(1):21-32
pubmed: 28133813
Science. 2010 Aug 13;329(5993):856-61
pubmed: 20616233
J Virol. 2014 Oct;88(20):11955-64
pubmed: 25100844
Nature. 1988 Jan 7;331(6151):82-4
pubmed: 3257544

Auteurs

Gregory M Martin (GM)

Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA. gmartin@scripps.edu.

Rebecca A Russell (RA)

The Sir William Dunn School of Pathology, The University of Oxford, Oxford, UK.

Philip Mundsperger (P)

Polymun Scientific Immunbiologische Forschung GmbH, Klosterneuburg, Austria.
Department of Biotechnology, University of Natural Resources and Life Sciences, Vienna, Austria.

Scarlett Harris (S)

The Sir William Dunn School of Pathology, The University of Oxford, Oxford, UK.

Lu Jovanoska (L)

The Sir William Dunn School of Pathology, The University of Oxford, Oxford, UK.

Luiza Farache Trajano (LF)

The Sir William Dunn School of Pathology, The University of Oxford, Oxford, UK.

Torben Schiffner (T)

The Sir William Dunn School of Pathology, The University of Oxford, Oxford, UK.
Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA, USA.

Katalin Fabian (K)

Department of Immunology, National Food Chain Safety Office, Directorate of Veterinary Medicinal Products, Budapest, Hungary.

Monica Tolazzi (M)

Viral Evolution and Transmission Unit, Division of Immunology, Transplantation, and Infectious Diseases, IRCCS Ospedale San Raffaele, Milan, Italy.

Gabriella Scarlatti (G)

Viral Evolution and Transmission Unit, Division of Immunology, Transplantation, and Infectious Diseases, IRCCS Ospedale San Raffaele, Milan, Italy.

Leon McFarlane (L)

Imperial College London, Department of Medicine, Division of Infectious Diseases, Section of Virology, Norfolk Place, London, W2 1PG, UK.

Hannah Cheeseman (H)

Imperial College London, Department of Medicine, Division of Infectious Diseases, Section of Virology, Norfolk Place, London, W2 1PG, UK.

Yoann Aldon (Y)

Imperial College London, Department of Medicine, Division of Infectious Diseases, Section of Virology, Norfolk Place, London, W2 1PG, UK.

Edith E Schermer (EE)

Department of Medical Microbiology, Academic Medical Centre University of Amsterdam, Amsterdam, The Netherlands.

Marielle Breemen (M)

Department of Medical Microbiology, Academic Medical Centre University of Amsterdam, Amsterdam, The Netherlands.

Kwinten Sliepen (K)

Department of Medical Microbiology, Academic Medical Centre University of Amsterdam, Amsterdam, The Netherlands.

Dietmar Katinger (D)

Polymun Scientific Immunbiologische Forschung GmbH, Klosterneuburg, Austria.

Renate Kunert (R)

Department of Biotechnology, University of Natural Resources and Life Sciences, Vienna, Austria.

Rogier W Sanders (RW)

Department of Medical Microbiology, Academic Medical Centre University of Amsterdam, Amsterdam, The Netherlands.

Robin Shattock (R)

Imperial College London, Department of Medicine, Division of Infectious Diseases, Section of Virology, Norfolk Place, London, W2 1PG, UK.

Andrew B Ward (AB)

Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, USA. andrew@scripps.edu.

Quentin J Sattentau (QJ)

The Sir William Dunn School of Pathology, The University of Oxford, Oxford, UK. quentin.sattentau@path.ox.ac.uk.

Classifications MeSH